Lyell Immunopharma, Inc. (LYEL): Total Liabilities
$91.85M
As of 2025-12-31
$77.34M
As of 2026-06-30
-4.2%
3-year compound annual growth
-13.5%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $91.85M | -15.0% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $108.03M | +13.6% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $95.08M | -8.9% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $104.31M | -47.2% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $197.62M | +4.1% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $189.84M | n/a | 2022-03-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $91.85M | -15.0% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $20.33M | +127.9% |
| Impact Biomedical Inc. (IBO) | 2025-12-31 | $1.85M | -85.8% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $55.04M | +248.4% |
| Talphera, Inc. (TLPH) | 2025-12-31 | $12.68M | +23.9% |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $21.76M | -41.2% |
| Avalo Therapeutics, Inc. (AVTX) | 2025-12-31 | $33.41M | +88.8% |
| Jupiter Neurosciences, Inc. (JUNS) | 2025-12-31 | $7.40M | +264.3% |
| Connect Biopharma Holdings Ltd (CNTB) | 2025-12-31 | $14.10M | +54.6% |
Compare LYEL, NTHI, IBO, ALT side by side · Screen every company in Pharmaceutical Preparations ↗